Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
312 participants
OBSERVATIONAL
2011-10-15
2024-05-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efgartigimod for the Treatment of Guillain-Barré Syndrome
NCT06885762
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
NCT06299748
Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
NCT01625182
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
NCT02100969
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
NCT05701189
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
fingolimod
prescribed fingolimod 0.5 mg/day, including generic versions of fingolimod
Fingolimod
fingolimod 0.5 mg/day, including generic versions of fingolimod
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fingolimod
fingolimod 0.5 mg/day, including generic versions of fingolimod
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any woman currently pregnant
* Exposure to fingolimod during pregnancy or up to 8 weeks before LMP
* Signed informed consent
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Novartis Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novartis Investigative Site
Fort Lauderdale, Florida, United States
Novartis Investigative Site
Cambridge, Massachusetts, United States
Novartis Investigative Site
Grand Forks, North Dakota, United States
Novartis Investigative Site
Bahía Blanca, Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, , Argentina
Novartis Investigative Site
Box Hill, Victoria, Australia
Novartis Investigative Site
Graz, , Austria
Novartis Investigative Site
Linz, , Austria
Novartis Investigative Site
Brasschaat, , Belgium
Novartis Investigative Site
Leuven, , Belgium
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Saint-Laurent, Quebec, Canada
Novartis Investigative Site
Bogotá, , Colombia
Novartis Investigative Site
Nicosia, , Cyprus
Novartis Investigative Site
Ostrava-Poruba, , Czechia
Novartis Investigative Site
Aalborg, , Denmark
Novartis Investigative Site
Aarhus, , Denmark
Novartis Investigative Site
Copenhagen, , Denmark
Novartis Investigative Site
Sønderborg, , Denmark
Novartis Investigative Site
Tampere, , Finland
Novartis Investigative Site
Turku, , Finland
Novartis Investigative Site
Bron, , France
Novartis Investigative Site
Cahors, , France
Novartis Investigative Site
Bochum, , Germany
Novartis Investigative Site
Athens, GR, Greece
Novartis Investigative Site
Budapest, HUN, Hungary
Novartis Investigative Site
Győr, , Hungary
Novartis Investigative Site
Dublin, , Ireland
Novartis Investigative Site
Jerusalem, , Israel
Novartis Investigative Site
Ramat Gan, , Israel
Novartis Investigative Site
Catania, CT, Italy
Novartis Investigative Site
Florence, FI, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Roma, RM, Italy
Novartis Investigative Site
Orbassano, TO, Italy
Novartis Investigative Site
Beirut, , Lebanon
Novartis Investigative Site
Mexico City, Mexico City, Mexico
Novartis Investigative Site
Amsterdam, , Netherlands
Novartis Investigative Site
Lubin, , Poland
Novartis Investigative Site
Warsaw, , Poland
Novartis Investigative Site
Amadora, , Portugal
Novartis Investigative Site
Porto, , Portugal
Novartis Investigative Site
Bucharest, , Romania
Novartis Investigative Site
Moscow, , Russia
Novartis Investigative Site
Jeddah, , Saudi Arabia
Novartis Investigative Site
Riyadh, , Saudi Arabia
Novartis Investigative Site
Bratislava, Slovak Republic, Slovakia
Novartis Investigative Site
Maribor, , Slovenia
Novartis Investigative Site
Seville, Andalusia, Spain
Novartis Investigative Site
Madrid, , Spain
Novartis Investigative Site
Gothenburg, , Sweden
Novartis Investigative Site
Basel, , Switzerland
Novartis Investigative Site
Bern, , Switzerland
Novartis Investigative Site
Lausanne, , Switzerland
Novartis Investigative Site
Sankt Gallen, , Switzerland
Novartis Investigative Site
Abu Dhabi, , United Arab Emirates
Novartis Investigative Site
Dubai, , United Arab Emirates
Novartis Investigative Site
Newcastle upon Tyne, , United Kingdom
Novartis Investigative Site
Norwich, , United Kingdom
Novartis Investigative Site
Nottingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
https://www.gilenyapregnancyregistry.com
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFTY720D2404
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.